|
| Interactions: | Acenocoumarol
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Felodipine and Acenocoumarol should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Amiodarone
Adverse Effect: Atrioventricular block and slowing of sinus rate
Clinical Management: Concurrent use of amiodarone and Felodipine should be avoided in patients with sick sinus syndrome or partial AV (atrioventricular) block.
Atenolol Adverse Effect: Hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Betaxolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Bisoprolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Carbamazepine Adverse Effect: Decreased felodipine effectiveness
Clinical Management: Monitor clinical response to felodipine with dose adjustments as needed to achieve or maintain cardiovascular response. Felodipine does not appear to interact with carbamazepine and may be considered as an alternative to felodipine.
Carvedilol
Adverse Effect:hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Celecoxib Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Celiprolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
DigoxinAdverse Effect: Transient increases in the digoxin serum concentration
Clinical Management: Monitor the patient for signs of digoxin toxicity (nausea, vomiting, arrhythmias) when felodipine therapy is initiated. This especially applies to a patient who is already in the upper therapeutic digoxin concentration range or who is renally impaired.
ErythromycinAdverse Effect: Felodipine toxicity (flushing, edema, tachycardia)
Clinical Management: If concurrent therapy is required, monitor for felodipine toxicity (eg, tachycardia, edema, flushing). If adverse effects occur, either discontinue the use of erythromycin or lower the dose of felodipine and monitor the response.
EsmololAdverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
FluconazoleAdverse Effect: Increased felodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema)
Clinical Management: Observe for development of toxicity associated with the calcium channel blocker (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of Felodipine or withdrawing one of the agents.
Flurbiprofen Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
IbuprofenAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
IndinavirAdverse Effect: increase in the Plasma concentration of Calcium Channel Blockers like Felodipine due to inhibition of cytochrome P450 3A4
Clinical Management: Monitor for the adverse effect and administer the drugs with caution.
IndomethacinAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
ItraconazoleAdverse Effect: Increased felodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema)
Clinical Management: The concurrent use of itraconazole and felodipine should be avoided. If these agents must be used together, observe for development of toxicity associated with felodipine (peripheral edema, dizziness, hypotension, flushing, headache). Substantial decreases in the felodipine dose may be necessary.
KetoconazoleAdverse Effect: increased Felodipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema)
Clinical Management: Observe for development of toxicity associated with Felodipine (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of Felodipine or withdrawing one of the agents.
KetoprofenAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
KetorolacAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Labetalol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
LevobunololAdverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Mefenamic Acid Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
MeloxicamAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
MetoprololAdverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Mg. saltsAdverse Effect: Hypotension
Clinical Management: Monitor blood pressure closely when adding or deleting Felodipine in patients receiving magnesium.
Nabumetone Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Naproxen Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
NimesulideAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
OxcarbazepineAdverse Effect: Felodipine AUC was lowered
Clinical Management: Monitor for therapeutic effects and adjust the dose accordingly.
Oxprenolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Oxyphenbutazone Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
ParacetamolAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
PhenacetinAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenindione Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Felodipine and Phenindione should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Phenobarbitone Adverse Effect: Decreased felodipine effectiveness
Clinical Management: Monitor patient for loss of Felodipine effects, including clinical signs or symptoms of hypertension or angina. Dose increases may be required.
PhenylbutazoneAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenytoin Adverse Effect: Decreased felodipine effectiveness
Clinical Management: Monitor for continuing clinical effectiveness of felodipine. Larger than expected doses may be required. Other Felodipine may be tried cautiously since some of these agents have been shown to interact with phenytoin to produce symptomatic, toxic elevations in serum phenytoin levels. Use of an alternative therapeutic class of drug (ACE inhibitors, for example) may be required to minimize the possibility for a phenytoin interaction.
PindololAdverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Piroxicam Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Propranolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
RifampicinAdverse Effect: Decreased felodipine efficacy
Tenoxicam Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Theophylline Adverse Effect: A decrease of theophylline efficacy
Clinical Management: Theophylline serum concentrations should be closely monitored when felodipine is added, discontinued, or when dosing changes occur. Dosing adjustments of theophylline may be necessary.
Timolol Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Warfarin Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Felodipine and Warfarin should be monitored for excessive bleeding, especially from the gastrointestinal tract. |
|
|